PriceTargets.com logo

Viela Bio - VIE Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$53.01 As of 03/15/2021 01:00 AM ET
+0 (0.00%)
Get New Viela Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Viela Bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $53.01.

This chart shows the closing price for VIE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Viela Bio. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/8/2021GuggenheimDowngradeBuy ➝ Neutral
2/8/2021WedbushDowngradeOutperform ➝ Neutral$43.00
2/2/2021HC WainwrightDowngradeBuy ➝ Neutral$52.00 ➝ $53.00
11/12/2020HC WainwrightLower TargetBuy$75.00 ➝ $52.00
11/11/2020WedbushLower TargetOutperform$60.00 ➝ $50.00
10/26/2020HC WainwrightLower TargetBuy$82.00 ➝ $75.00
8/13/2020Stifel NicolausReiterated RatingHold$48.00
8/13/2020WedbushLower TargetOutperform$63.00 ➝ $60.00
8/13/2020HC WainwrightBoost TargetBuy$76.00 ➝ $82.00
7/15/2020The Goldman Sachs GroupUpgradeSell ➝ Neutral$48.00 ➝ $49.00
6/12/2020HC WainwrightBoost TargetBuy$70.00 ➝ $76.00
6/8/2020Stifel NicolausInitiated CoverageHold$58.00
6/3/2020CowenReiterated RatingBuy$73.00
5/14/2020GuggenheimBoost TargetBuy$51.00 ➝ $78.00
5/14/2020WedbushBoost TargetOutperform$62.00 ➝ $63.00
5/14/2020Morgan StanleyBoost TargetOverweight$54.00 ➝ $55.00
5/14/2020HC WainwrightReiterated RatingBuy$60.00 ➝ $70.00
4/28/2020WedbushInitiated CoverageOutperform$62.00
4/6/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$36.00
3/26/2020Morgan StanleyBoost TargetOverweight$35.00 ➝ $54.00
2/18/2020HC WainwrightInitiated CoverageBuy$60.00
2/4/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$36.00
12/17/2019Morgan StanleyBoost TargetOverweight$25.00 ➝ $35.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Viela Bio logo
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $53.01
Low: $53.01
High: $53.01

50 Day Range

MA: $53.01
Low: $52.92
High: $53.20

52 Week Range

Now: $53.01
Low: $25.02
High: $65.00

Volume

N/A

Average Volume

1,065,058 shs

Market Capitalization

$2.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Viela Bio?

The following Wall Street sell-side analysts have issued stock ratings on Viela Bio in the last twelve months:
View the latest analyst ratings for VIE.

What is the current price target for Viela Bio?

0 Wall Street analysts have set twelve-month price targets for Viela Bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Viela Bio in the next year.
View the latest price targets for VIE.

What is the current consensus analyst rating for Viela Bio?

Viela Bio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VIE.

What other companies compete with Viela Bio?

Other companies that are similar to Viela Bio include Catalent, Roivant Sciences, Intra-Cellular Therapies, Ascendis Pharma A/S and Legend Biotech. Learn More about companies similar to Viela Bio.

How do I contact Viela Bio's investor relations team?

Viela Bio's physical mailing address is 1 MEDIMMUNE WAY, GAITHERSBURG MD, 20878. The company's listed phone number is 240 558 0038 and its investor relations email address is [email protected]. The official website for Viela Bio is www.vielabio.com. Learn More about contacing Viela Bio investor relations.